Liquidia Corp stock (US53634H1077): momentum rally puts valuation metrics in focus after strong year-to-date gains

Liquidia shares on Nasdaq continue to trade near their 52-week high after a sharp year-to-date move, drawing attention to valuation metrics as investors weigh progress in pulmonary hypertension therapies against ongoing losses.

Liquidia Corp shares continued to trade close to their recent highs on the Nasdaq in the United States, extending a strong year-to-date run that has pushed the biopharmaceutical stock to the top tier of momentum names in the US healthcare space, according to a momentum screen by Zacks published in May 2026 that highlighted an advance of more than 80% over the past year and a Zacks Rank of 1 (Strong Buy) as of that date, while German investors can also access the stock via secondary quotations such as Tradegate in euros, even though core liquidity remains centered in the US market, as underlined by Nasdaq pricing data for ticker LQDA on 05/28/2026.

According to a real-time quote snapshot for Liquidia Corp on 05/28/2026, the stock last traded around USD 62 on the Nasdaq, barely below its 52-week high, after delivering a one-year performance of roughly 300% and a monthly performance of close to 60%, which places the company among the strongest-performing US biotechnology names over both horizons, while the same data set indicates that the share price is currently more than 400% above its 52-week low, underscoring the scale of the rerating that has taken place as investors have reassessed the commercial prospects of its pulmonary hypertension pipeline.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Liquidia Corp
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Morrisville, United States
• Core markets: United States pulmonary hypertension and related respiratory indications
• Key revenue drivers: Inhaled treprostinil product candidate YUTREPIA and generic Treprostinil injection products in the US
• Home exchange/listing venue: Nasdaq (LQDA)
• Trading currency: USD

Liquidia Corp: core business model

Liquidia focuses on developing and commercializing specialty biopharmaceutical therapies for pulmonary hypertension in the United States, with potential revenue anchored in its PRINT-enabled inhaled treprostinil product candidate YUTREPIA and related treprostinil formulations for patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension.

Valuation metrics and multiples for Liquidia Corp

The sharp rerating in Liquidia Corp over the past 12 months has left the company trading on growth-oriented valuation metrics that are less about traditional earnings multiples and more about expectations for future cash flows from its pulmonary hypertension franchise, as the company remains loss-making on a GAAP basis. In an April 2026 narrative update, Simply Wall St summarized that Liquidia is still forecast to post a net loss per share of around USD 1.33 next year compared with an expected net loss per share of roughly USD 1.21 for the current year, highlighting that the market is effectively valuing the shares on a price-to-sales and pipeline-adjusted basis rather than on near-term profitability, and the service also pointed to a consensus analyst price target in the mid-40 USD range at that time, which was below the current spot price near USD 62 but still significantly above levels seen at the beginning of the current 12-month period.

The absence of a meaningful trailing price-earnings ratio, given ongoing net losses, means investors are focusing instead on valuation indicators such as enterprise value to expected future sales from YUTREPIA and other treprostinil products, while momentum indicators have also become relevant for shorter-term traders. Zacks, in a May 2026 momentum-focused article, noted that Liquidia had delivered an average earnings surprise of more than 50% over the last four reported quarters, with three beats and one miss, which has contributed to the stock's momentum characteristics and the maintenance of a favorable Zacks Rank; these dynamics, combined with a share price that has climbed more than 80% over 12 months and around 60% in the most recent month, imply that valuation multiples may already reflect a sizable portion of anticipated clinical and regulatory progress, even though the company is still in the loss-making phase and remains exposed to binary outcomes around future approvals and market uptake of its pulmonary hypertension therapies.

Conclusion

Liquidia Corp's stock is trading close to its 52-week high on the Nasdaq after a sharp 12-month rally supported by positive momentum indicators and stronger-than-expected earnings versus consensus in three of the last four quarters. With the company still forecast to post net losses next year and valuation increasingly tied to expectations for its pulmonary hypertension pipeline rather than current profitability, investors are scrutinizing metrics such as enterprise value relative to anticipated sales from YUTREPIA and related treprostinil therapies. The current price level near USD 62, well above recent analyst target averages but backed by strong recent performance data, underlines how sensitive the share could be to upcoming regulatory, clinical and competitive developments in the pulmonary arterial hypertension market.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.